Biologics and Biosimilars: Background and Key Issues Agata Dabrowska Analyst in Health Policy Updated June 6, 2019 Cong, FDA Risk Evaluation and Miti
制药Tag内容描述：
1、 Biologics and Biosimilars: Background and Key Issues Agata Dabrowska Analyst in Health Policy Updated June 6, 2019 Cong。
2、 FDA Risk Evaluation and Mitigation Strategies REMS: Description and Effect on Generic Drug Development name redacted An。
3、CRS INSIGHT Prepared for Members and Committees of Congress Legal SidebarLegal Sidebari i All Eyes on Allergan: Drug Com。
4、 Generic Drugs and GDUFA Reauthorization: In Brief name redacted Specialist in Biomedical Policy July 5, 2017 Congressio。
5、CRS Report for CongressPrepared for Members and Committees of Congress Drug Patent Expirations: Potential Effects on Pha。
6、CRS Report for CongressPrepared for Members and Committees of Congress Proposed FDA User Fee Acts: Generic Drug User Fee。
7、CRS Report for CongressPrepared for Members and Committees of Congress Federal Taxation of the Drug Industry and Its Eff。
8、Congressional Research Service The Library of CongressCRS Report for CongressReceived through the CRS WebOrder Code RL30。
